Premium
P4‐127: Exploring the Utility of CSF Neurogranin Levels in An Alzheimer’s Disease Clinical Trial
Author(s) -
Dage Jeffrey L.,
Castelluccio Peter F.,
Anderson Wesley,
Yu Peng,
Talbot Jayne,
Miller Bradley B.,
Herries Elizabeth M.,
Crimmins Dan,
Ladenson Jack H.,
Fagan Anne M.,
Holtzman David M.,
Henley David B.,
Siemers Eric R.,
Dean Robert A.
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.06.2218
Subject(s) - neurogranin , cerebrospinal fluid , medicine , biomarker , oncology , clinical trial , disease , lumbar puncture , pathology , gastroenterology , biochemistry , protein kinase c , enzyme , chemistry
stratified, multi-modal biomarker assessed AD cases and controls to define a novel array of single nucleotide polymorphism (SNP) markers. This panel, which performed with high levels of accuracy (AUC) in differentiating AD and controls in an independent test set of samples, has now been used for SNP genotyping, using the Affymetrix Axiom Genotyping Technology, of additional clinical samples obtained as part of observational studies. Results: Samples were analysed from amyloid-positive and amyloid-negative aged-matched individuals who were either cognitively normal or previously diagnosed with Mild Cognitive Impairment (MCI). On the basis that amyloid positivity, as determined by positron emission tomography (PET), is considered to represent a significant risk factor for future progression to AD, we have conducted analyses to determine potential relationships between amyloid status and SNP profiles in these groups. Conclusions: The results from these analyses provide indications as to the potential utility of SNP genotyping arrays in the risk profiling of early symptomatic and pre-symptomatic individuals.